However, due to the limited evidence, further research should be performed on the safety of anti-VEGF administration in patients with different corneal disorders.
Corneal disease is characterized by loss of corneal immunologic privilege and extensive neovascularization driven by vascular endothelial growth factor-A (VEGF-A).